Keebeck Alpha LP acquired a new position in ChromaDex Co. (NASDAQ:CDXC) during the first quarter, according to the company in its most recent filing with the SEC. The fund acquired 10,738 shares of the company’s stock, valued at approximately $100,000.
A number of other hedge funds have also recently modified their holdings of CDXC. Citigroup Inc. lifted its holdings in ChromaDex by 302.8% in the 4th quarter. Citigroup Inc. now owns 7,886 shares of the company’s stock worth $38,000 after buying an additional 5,928 shares in the last quarter. Principal Financial Group Inc. acquired a new position in ChromaDex in the 4th quarter worth $51,000. Ahrens Investment Partners LLC acquired a new position in ChromaDex in the 4th quarter worth $53,000. Hancock Whitney Corp acquired a new position in ChromaDex in the 4th quarter worth $60,000. Finally, Credit Suisse AG acquired a new position in ChromaDex in the 4th quarter worth $63,000. Hedge funds and other institutional investors own 24.74% of the company’s stock.
Shares of ChromaDex stock opened at $6.90 on Monday. ChromaDex Co. has a 1 year low of $3.82 and a 1 year high of $23.66. The firm’s 50-day simple moving average is $8.63 and its 200-day simple moving average is $6.98. The firm has a market cap of $468.74 million, a PE ratio of -18.16 and a beta of 1.49.
In related news, Director Stephen A. Block sold 20,000 shares of the business’s stock in a transaction dated Tuesday, March 16th. The shares were sold at an average price of $13.17, for a total transaction of $263,400.00. Following the completion of the sale, the director now owns 49,167 shares of the company’s stock, valued at approximately $647,529.39. The sale was disclosed in a legal filing with the SEC, which is available through this link. 12.92% of the stock is owned by corporate insiders.
A number of equities analysts have commented on CDXC shares. B. Riley boosted their price objective on shares of ChromaDex from $7.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, March 8th. Zacks Investment Research upgraded shares of ChromaDex from a “sell” rating to a “hold” rating in a research note on Tuesday, May 11th. HC Wainwright cut their target price on shares of ChromaDex to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 10th. Finally, Oppenheimer assumed coverage on shares of ChromaDex in a research note on Wednesday, March 10th. They issued a “buy” rating and a $9.00 target price on the stock.
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Featured Story: Capital Gains Distribution
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.